HomeALTME • EPA
add
TME Pharma NV
Previous close
€0.15
Day range
€0.14 - €0.15
Year range
€0.11 - €0.44
Market cap
6.15M EUR
Avg Volume
636.41K
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Market news
Investing.com
23 minutes ago
Fairlead Strategies says a bigger push higher in S&P 500 is likely coming
0.00%
Financials
Income Statement
Revenue
Net income
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 1.37M | -0.51% |
Net income | -1.62M | 11.23% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -1.34M | 0.07% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.70M | -10.14% |
Total assets | 2.94M | -15.02% |
Total liabilities | 1.38M | -62.07% |
Total equity | 1.57M | — |
Shares outstanding | 42.12M | — |
Price to book | 3.68 | — |
Return on assets | -116.29% | — |
Return on capital | -217.64% | — |
Cash Flow
Net change in cash
| (EUR) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -1.62M | 11.23% |
Cash from operations | -1.37M | 19.42% |
Cash from investing | -4.00K | 57.89% |
Cash from financing | 1.60M | 78.88% |
Net change in cash | 229.00K | 128.17% |
Free cash flow | -723.12K | 3.18% |
About
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller.
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes. Wikipedia
Founded
1997
Website
Employees
13
